Filing Details
- Accession Number:
- 0001209191-19-058217
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-26 20:01:00
- Reporting Period:
- 2019-11-22
- Accepted Time:
- 2019-11-26 20:01:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 873303 | Sarepta Therapeutics Inc. | SRPT | Pharmaceutical Preparations (2834) | 930797222 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1529297 | T David Howton | 215 First Street, Suite 415 Cambridge MA 02142 | Evp, General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-11-22 | 5,685 | $13.71 | 24,388 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-22 | 4,025 | $13.71 | 28,413 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-22 | 8,580 | $13.90 | 36,993 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-11-22 | 18,290 | $105.00 | 18,703 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-11-22 | 3,753 | $105.00 | 14,950 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-11-22 | 2,957 | $105.00 | 11,993 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-11-22 | 2,440 | $13.71 | 14,433 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-22 | 52 | $13.71 | 14,485 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-22 | 5,590 | $13.90 | 20,075 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-22 | 7,900 | $23.85 | 27,975 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-11-22 | 2,804 | $107.02 | 25,171 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2019-11-22 | 5,685 | $0.00 | 5,685 | $13.71 |
| Common Stock | Stock option (right to buy) | Disposition | 2019-11-22 | 4,025 | $0.00 | 4,025 | $13.71 |
| Common Stock | Stock option (right to buy) | Disposition | 2019-11-22 | 8,580 | $0.00 | 8,580 | $13.90 |
| Common Stock | Stock option (right to buy) | Disposition | 2019-11-22 | 2,440 | $0.00 | 2,440 | $13.71 |
| Common Stock | Stock option (right to buy) | Disposition | 2019-11-22 | 52 | $0.00 | 52 | $13.71 |
| Common Stock | Stock option (right to buy) | Disposition | 2019-11-22 | 5,590 | $0.00 | 5,590 | $13.90 |
| Common Stock | Stock option (right to buy) | Disposition | 2019-11-22 | 7,900 | $0.00 | 7,900 | $23.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,280 | 2017-02-28 | 2026-02-28 | No | 4 | M | Direct |
| 1,858 | 2016-09-19 | 2026-02-28 | No | 4 | M | Direct |
| 18,579 | 2016-02-27 | 2025-02-27 | No | 4 | M | Direct |
| 2,470 | 2017-02-28 | 2026-02-28 | No | 4 | M | Direct |
| 18 | 2016-09-19 | 2026-02-28 | No | 4 | M | Direct |
| 0 | 2016-02-27 | 2025-02-27 | No | 4 | M | Direct |
| 5,118 | 2013-11-05 | 2022-11-05 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
- Represents shares of Common Stock owned by the reporting person that were delivered to the Company to pay the aggregate exercise price with respect to the option exercises reported in rows 4-7 in Table II of this Form 4 filing.
Billionaire Hedge Funds
